



**TRANSGENE**  
**BIOTEK LIMITED**  
INNOVATING. FOR LIFE.

May 30, 2022

The General Manager  
Department of Corporate Services – CRD,  
Bombay Stock Exchange Limited (BSE),  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai 400 001.

**Scrip Code: 526139**

**Subject: Outcome of Board Meeting.**

Dear Sir/Madam,

This has reference to our letter dated May 08 2022.

- 1) Considered and Approved the Audited Consolidated & Stand-alone Financial Statement for the Quarter and Financial Year ended 31.03.2022 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules, 2015
- 2) Auditor's Report Consolidated & Standalone for the Quarter and Financial year ended submitted by M/s. Manisha Dubey & Associates, Chartered Accountants.
- 3) Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Consolidated & Standalone

This is for your kind information and records.

Thanking you

Yours faithfully,

**For TRANSGENE BIOTEK LIMITED**

**DR K KOTESWARA RAO**  
**CHAIRMAN & MANAGING DIRECTOR**

**TRANSGENE BIOTEK LIMITED**

 Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN  
 CIN NO: L85195TG1990PLC011065

**STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2022**

Sr. No.	Particulars	Quarter Ended			Year Ended	Year Ended
		31.03.2022 (Audited)	31.12.2021 (Unaudited)	31.03.2021 (Audited)	31.03.2022 (Audited)	31.03.2021 (Audited)
1	Revenue from operations	8,50,000	-	1,30,000	8,66,949	16,95,499
2	Other income (net)	8,09,914	4,38,470	12,81,417	21,25,324	26,68,984
3	<b>Total income (1 + 2)</b>	<b>16,59,914</b>	<b>4,38,470</b>	<b>14,11,417</b>	<b>29,92,273</b>	<b>43,64,483</b>
4	<b>EXPENSES</b>					
	Cost of materials consumed	56,678	1,32,752	2,27,039	2,18,069	4,29,068
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	(7,41,120)		1,79,212	(6,80,201)	1,79,212
	Employee benefits expense	7,88,510	7,79,734	3,19,469	28,78,842	24,59,236
	Finance costs	5,66,950	5,66,950	6,65,680	22,67,800	26,62,723
	Depreciation and amortisation expense	251,27,981	247,05,193	247,83,413	992,43,559	990,80,463
	Other expenses	13,10,036	6,84,341	12,99,474	30,84,248	38,85,247
	<b>Total expenses</b>	<b>271,09,035</b>	<b>268,68,970</b>	<b>274,74,287</b>	<b>1070,12,317</b>	<b>1086,95,949</b>
5	<b>Profit before exceptional items, share of profit from associate &amp; joint venture and tax (3 - 4)</b>	<b>(254,49,121)</b>	<b>(264,30,500)</b>	<b>(260,62,870)</b>	<b>(1040,20,044)</b>	<b>(1043,31,466)</b>
6	Exceptional item (net)	-	-	-	-	-
7	<b>Profit before tax (5 - 6)</b>	<b>(254,49,121)</b>	<b>(264,30,500)</b>	<b>(260,62,870)</b>	<b>(1040,20,044)</b>	<b>(1043,31,466)</b>
8	<b>Tax expense</b>					
	Tax adjustments for earlier years	-	-	-	-	-
	Current tax	-	-	-	-	-
	Deferred tax	-	-	-	-	-
	<b>Total tax expense</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
9	<b>Profit for the year (7 - 8)</b>	<b>(254,49,121)</b>	<b>(264,30,500)</b>	<b>(260,62,870)</b>	<b>(1040,20,044)</b>	<b>(1043,31,466)</b>
10	<b>Other comprehensive income</b>					
	A Items that will not be reclassified subsequently to profit or loss					
	(a) Remeasurements cost of post employment benefits	-	-	-	-	-
	<b>Total other comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
11	<b>Total comprehensive income for the year (9 + 10)</b>	<b>(254,49,121)</b>	<b>(264,30,500)</b>	<b>(260,62,870)</b>	<b>(1040,20,044)</b>	<b>(1043,31,466)</b>
12	<b>Earnings per equity share</b>					
	(Equity shares, par value of Rs. 10 each)					
	Basic (Rs.)	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000
	Diluted (Rs.)	(0.34)	(0.35)	(0.34)	(1.37)	(1.38)
		(0.34)	(0.35)	(0.34)	(1.37)	(1.38)

**Notes:**

1. "Nozulim" - Intra-Nasal delivery of Insulin: With sustained efforts we are now moving closer to initiating pre-clinical trials shortly with the anticipated regulatory approvals expected soon.
2. No. of investor complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0.
3. The auditors have carried out the audit of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 30th May 2022.
4. The appeal filed against the Income tax demand for FY 2011-12 (AY 2012-13) has been accepted and demand has been nullified by the department with order No ITA No.888/Hyd/2018 dated 24/08/2021. The provision has been created through Retained earnings in previous years hence reversed it through the same.

**For TRANSGENE BIOTEK LIMITED**
  
**Dr.K.Koteswara Rao**  
 Managing Director

 Date: 30.05.2022  
 Place: Hyderabad




# TRANSGENE BIOTEK LIMITED

69 & 70, TDA Bollaram, Sangareddy District - 502325, Telangana  
CIN NO: L85195TG1990PLC011065

## Standalone Statement of assets and liabilities

Particulars	As at March 31,2022	As at March 31,2021
<b>ASSETS</b>		
Non-current assets		
Property, plant and equipment	184,67,547	202,94,953
Capital Work in Progress	-	-
Other intangible assets	955,03,181	1929,19,335
Intangible assets under development	186,76,633	186,76,633
Financial assets	-	-
(a) Investments	10,50,140	99,990
(b) Loans	2302,04,250	2302,04,250
Other non-current assets	13,97,088	13,78,696
<b>Total Non - Current Assets</b>	<b>3652,98,839</b>	<b>4635,73,857</b>
Current Assets		
Inventories	9,46,220	2,05,100
Financial assets	-	-
(a) Cash and cash equivalents	1,51,227	1,41,743
Current Tax Assets	-	-
Other current assets	58,03,058	60,13,088
<b>Total Current assets</b>	<b>69,00,505</b>	<b>63,59,931</b>
<b>Total Assets</b>	<b>3721,99,345</b>	<b>4699,33,788</b>
<b>EQUITY AND LIABILITIES</b>		
Equity		
Equity share capital	7577,00,000	7577,00,000
Other equity	(7596,70,205)	(7110,61,972)
Equity attributable to owners of the Company	<b>(19,70,205)</b>	<b>466,38,028</b>
<b>Total Equity</b>	<b>(19,70,205)</b>	<b>466,38,028</b>
Non-current liabilities		
Financial Liabilities		
(a) Borrowings	476,89,968	454,22,168
Provisions	2302,04,250	2302,04,250
Other non-current liabilities	52,61,643	70,15,523
<b>Total Non-current liabilities</b>	<b>2831,55,861</b>	<b>2826,41,941</b>
Current liabilities		
Financial liabilities		
(a) Borrowings	724,66,000	678,77,576
(b) Trade payables	20,27,760	23,95,852
(d) Other financial liabilities measured at fair value	-	-
Provisions	141,47,676	693,49,390
Other current liabilities	23,72,254	10,31,002
<b>Total Current liabilities</b>	<b>910,13,690</b>	<b>1406,53,820</b>
<b>Total liabilities</b>		
<b>Total Equity and liabilities</b>	<b>3721,99,345</b>	<b>4699,33,788</b>

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao  
Managing Director

Date: 30.05.2022  
Place: Hyderabad







**TRANSGENE BIOTEK LIMITED**

69 & 70, IDA Bollaram, Sangareddy District - 502325, Telangana  
Standalone Statement of Cash Flows for the year ended 31-03-2022

Particulars	For the year ended March 31, 2022		For the year ended March 31, 2021	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
<b>Profit before tax</b>		(1040,20,044)		(1043,31,466)
<u>Adjustments for :</u>				
Depreciation and amortisation expense	992,43,560		990,80,463	
Finance costs	22,67,800		26,62,723	
Amortisation of government grant	(17,53,880)		(17,53,880)	
Supplier Advances Written off	-		-	
Bad debts written off	-		-	
Profit or loss on sale of Fixed asset	-		-	
Other Non cash Expenses	-		-	
<b>Operating profit before working capital changes</b>		<b>(42,62,564)</b>		<b>(43,42,160)</b>
<u>Changes in working capital:</u>				
<u>Adjustments for (increase) / decrease in operating assets:</u>				
Trade receivables			-	
Other non-current assets	(18,392)		(3,99,947)	
Other Current assets	2,10,030		(53,627)	
Inventories	(7,41,120)		1,79,212	
<u>Adjustments for increase / (decrease) in operating liabilities:</u>				
Trade payables	(3,68,092)		(14,00,100)	
Provision (CL)	2,10,097		(5,52,397)	
Borrowing (CL)	45,88,424		73,69,278	
Other financial liabilities				
Other current liabilities	13,41,252		(6,74,580)	
Provision (NCL)			-	
<b>Cash generated from operations</b>		<b>9,59,635</b>		<b>1,25,679</b>
Net income tax paid		-		-
<b>Net cash flow from operating activities (A)</b>		<b>9,59,635</b>		<b>1,25,679</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Capital expenditure on fixed assets, including capital advances			(2,73,851)	
Investments	(9,50,150)		(99,990)	
Proceeds from sale of fixed assets			-	
<b>Net cash (used in) / flow from investing activities (B)</b>		<b>(9,50,150)</b>		<b>(3,73,841)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds from issue of equity shares				
Finance costs				
Proceeds from Borrowings				
Payment of Borrowing				-
<b>Net cash flow (used in) financing activities (C)</b>		<b>-</b>		<b>-</b>
<b>Net (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>9,485</b>		<b>(2,48,162)</b>
<b>Cash and cash equivalents at the beginning of the year</b>		<b>1,41,743</b>		<b>3,89,905</b>
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
<b>Cash and cash equivalents at the end of the year</b>		<b>1,51,227</b>		<b>1,41,743</b>

For and on behalf of the Board of Directors

**M/s TRANSGENE BIOTEK LIMITED**

**Dr.K K Koteswara Rao**

Chairman & Managing Director

DIN:02287235

Place: Hyderabad

Date: 30.05.2022



**STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 2022**

(Amount in Rs.)

Sr. No.	Particulars	Quarter Ended			Year Ended	Year Ended
		31.03.2022 (Audited)	31.12.2021 (Unaudited)	31.03.2021 (Audited)	31.03.2022 (Audited)	31.03.2021 (Audited)
1	Revenue from operations	8,50,000	-	1,30,000	8,66,949	16,95,499
2	Other income (net)	8,09,914	4,38,470	12,81,417	21,25,324	26,68,984
3	<b>Total income (1 + 2)</b>	<b>16,59,914</b>	<b>4,38,470</b>	<b>14,11,417</b>	<b>29,92,273</b>	<b>43,64,483</b>
4	<b>EXPENSES</b>					
	Cost of materials consumed	56,678	1,32,752	2,27,039	2,21,069	4,29,068
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	(7,41,120)		1,79,212	(6,80,201)	1,79,212
	Employee benefits expense	7,88,510	7,79,734	3,19,469	28,78,842	24,59,236
	Finance costs	5,66,950	5,66,950	6,65,680	22,67,800	26,62,723
	Depreciation and amortisation expense	251,27,981	247,05,193	247,83,413	992,43,559	990,80,463
	Other expenses	13,13,436	6,84,341	12,99,474	30,89,859	38,85,247
	<b>Total expenses</b>	<b>271,12,435</b>	<b>268,68,970</b>	<b>274,74,287</b>	<b>1070,20,928</b>	<b>1086,95,949</b>
5	<b>Profit before exceptional items, share of profit from associate &amp; joint venture and tax (3 - 4)</b>	<b>(254,52,521)</b>	<b>(264,30,500)</b>	<b>(260,62,870)</b>	<b>(1040,28,655)</b>	<b>(1043,31,466)</b>
6	Exceptional item (net)	-	-	-	-	-
7	<b>Profit before tax (5 - 6)</b>	<b>(254,52,521)</b>	<b>(264,30,500)</b>	<b>(260,62,870)</b>	<b>(1040,28,655)</b>	<b>(1043,31,466)</b>
8	<b>Tax expense</b>					
	Tax adjustments for earlier years	-	-	-	-	-
	Current tax	-	-	-	-	-
	Deferred tax	-	-	-	-	-
	<b>Total tax expense</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
9	<b>Profit for the year (7 - 8)</b>	<b>(254,52,521)</b>	<b>(264,30,500)</b>	<b>(260,62,870)</b>	<b>(1040,28,655)</b>	<b>(1043,31,466)</b>
10	<b>Other comprehensive income</b>					
	A Items that will not be reclassified subsequently to profit or loss					
	(a) Remeasurements cost of post employment benefits	-	-	-	-	-
	<b>Total other comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
11	<b>Total comprehensive income for the year (9 + 10)</b>	<b>(254,52,521)</b>	<b>(264,30,500)</b>	<b>(260,62,870)</b>	<b>(1040,28,655)</b>	<b>(1043,31,466)</b>
12	<b>Earnings per equity share</b>					
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.34)	(0.35)	(0.34)	(1.37)	(1.38)
	Diluted (Rs.)	(0.34)	(0.35)	(0.34)	(1.37)	(1.38)

**Notes:**

1. "Nozulim" - Intra-Nasal delivery of Insulin: With sustained efforts we are now moving closer to initiating pre-clinical trials shortly with the anticipated regulatory approvals expected soon.
2. No. of investor complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0.
3. The auditors have carried out the audit of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 30th May 2022.
4. The appeal filed against the Income tax demand for FY 2011-12 (AY 2012-13) has been accepted and demand has been nullified by the department with order No ITA No.888/Hyd/2018 dated 24/08/2021. The provision has been created through Retained earnings in previous

**For TRANSGENE BIOTEK LIMITED**
  
**Dr.K.Koteswara Rao**  
 Managing Director

 Date: 30.05.2022  
 Place: Hyderabad


**TRANSGENE BIOTEK LIMITED**

67 & 70, IDA Bollaram, Sangareddy District - 502325, Telangana  
CIN NO: L85195TG1990PLC011065

**Consolidated Statement of Assets and Liabilities**

Particulars	As at March 31,2022	As at March 31,2021
<b>ASSETS</b>		
Non-current assets		
Property, plant and equipment	184,67,547	202,94,953
Capital Work in Progress	-	-
Other intangible assets	955,03,181	1929,19,335
Intangible assets under development	186,76,633	186,76,633
Financial assets	-	-
(a) Investments	9,50,150	-
(b) Loans	13290,24,004	13290,24,004
Other non-current assets	13,97,088	13,78,696
<b>Total Non - Current Assets</b>	<b>14640,18,603</b>	<b>15622,93,621</b>
<b>Current Assets</b>		
Inventories	9,46,220	2,05,100
Financial assets	-	-
(a) Cash and cash equivalents	1,51,227	2,41,743
(b) Trade Receivables	84,460	84,460
Current Tax Assets	-	-
Other current assets	58,03,058	59,97,716
<b>Total Current assets</b>	<b>69,84,965</b>	<b>65,29,019</b>
<b>Total Assets</b>	<b>14710,03,568</b>	<b>15688,22,640</b>
<b>EQUITY AND LIABILITIES</b>		
Equity		
Equity share capital	7577,00,010	7577,00,010
Other equity	(5839,26,013)	(5353,09,169)
Equity attributable to owners of the Company	<b>1737,73,997</b>	<b>2223,90,841</b>
<b>Total Equity</b>	<b>1737,73,997</b>	<b>2223,90,841</b>
Non-current liabilities		
Financial Liabilities		
(a) Borrowings	476,89,968	454,22,168
Provisions	11522,13,978	11522,13,978
Other non-current liabilities	52,61,643	70,15,523
<b>Total Non-current liabilities</b>	<b>12051,65,589</b>	<b>12046,51,669</b>
Current liabilities		
Financial liabilities		
(a) Borrowings	723,89,981	678,77,576
(b) Trade payables	20,27,760	23,95,852
(d) Other financial liabilities measured at fair value	11,26,311	11,26,311
Provisions	141,47,676	693,49,390
Other current liabilities	23,72,254	10,31,002
<b>Total Current liabilities</b>	<b>920,63,982</b>	<b>1417,80,131</b>
<b>Total liabilities</b>		
<b>Total Equity and liabilities</b>	<b>14710,03,568</b>	<b>15688,22,640</b>

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao  
Managing Director

Date: 30.05.2022  
Place:Hyderabad





**TRANSGENE BIOTEK LIMITED**

69 & 70, IDA Bollaram, Sangareddy District - 502325, Telangana  
Consolidated Statement of Cash Flows for the year ended 31-03-2022

Particulars	For the year ended March 31, 2022		For the year ended March 31, 2021	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
<b>Profit before tax</b>		(1040,28,655)		(1043,46,837)
<b>Adjustments for :</b>				
Depreciation and amortisation expense	992,43,560		990,80,463	
Finance costs	22,67,800		26,62,723	
Amortisation of government grant	(17,53,880)		(17,53,880)	
Supplier Advances Written off	-		-	
Bad debts written off	-		-	
Profit or loss on sale of Fixed asset	-		-	
Other Non cash Expenses	-		-	
<b>Operating profit before working capital changes</b>		(42,71,175)		(43,57,531)
<b>Changes in working capital:</b>				
<i>Adjustments for (increase) / decrease in operating assets:</i>				
Trade receivables			-	
Other non-current assets	(18,392)		(3,99,947)	
Other Current assets	1,94,658		(38,255)	
Inventories	(7,41,120)		1,79,212	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>				
Trade payables	(3,68,092)		(14,00,100)	
Provision (CL)	2,10,097		(5,52,397)	
Borrowing (CL)	45,12,405		73,69,278	
Other financial liabilities				
Other current liabilities	13,41,252		(6,74,580)	
Provision (NCL)			-	
<b>Cash generated from operations</b>		8,59,633		1,25,680
Net income tax paid		-		-
<b>Net cash flow from operating activities (A)</b>		8,59,633		1,25,680
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Capital expenditure on fixed assets, including capital advances			(2,73,851)	
Investments	(9,50,150)		-	
Proceeds from sale of fixed assets			-	
<b>Net cash (used in) / flow from investing activities (B)</b>		(9,50,150)		(2,73,851)
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds from issue of equity shares			10	
Finance costs				
Proceeds from Borrowings				
Payment of Borrowing				-
<b>Net cash flow (used in) financing activities (C)</b>		-		10
<b>Net (decrease) in Cash and cash equivalents (A+B+C)</b>		(90,517)		(1,48,161)
<b>Cash and cash equivalents at the beginning of the year</b>		2,41,744		3,89,905
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
<b>Cash and cash equivalents at the end of the year</b>		1,51,227		2,41,744

For and on behalf of the Board of Directors

M/s TRANSGENE BIOTEK LIMITED

**Dr.K K Koteswara Rao**  
Chairman & Managing Director  
DIN:02287235



Place: Hyderabad  
Date: 30.05.2022





**Auditor's report on quarterly and year to date Audited Standalone financial results for the period ended 31 March 2022 of Transgene Biotek Limited pursuant to Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
Board of Directors of  
Transgene Biotek Limited

**Report on the Audit of Standalone Financial Results**

**Opinion**

We have audited the accompanying statement of quarterly financial results of TRANSGENE BIOTEK Limited for the quarter ended 31 March 2022 and the year to date standalone financial results for the period 01 April 2020 to 31 March 2022, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:


- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. gives a true and fair view of the net profit/(Loss) and other financial information for the quarter ended 31 March 2022 as well as the year to date results for the period from 01 April 2021 to 31 March 2022.

**Basis of Opinion**

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

**Management Responsibilities for the Financial Results**

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive Income of the Company and other financial Information, in accordance with the applicable accounting standards prescribed under Section '133 of the Act read with relevant rules issued there under and other





accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either Intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.


#### **Other Matter**

The Statement includes the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2022 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

We draw attention Note 01 to the statement, which describes the business impact and uncertainties arising from COVID 19 pandemic. This is based on current facts and circumstances and may not reflect future uncertainties and events arising from the full impact of the COVID 19 pandemic.

For Manisha Dubey & Associates  
Chartered Accountants  
Firm's Registration No. 0001145

Manisha Dubey  
Proprietor  
Membership No. 212664  
Hyderabad



**Unique Document Identification Number (UDIN) for this document is 22212664AJWDTN7867**



**Auditor's report on quarterly and year to date Audited Consolidated financial results for the period ended 31 March 2022 of Transgene Biotek Limited pursuant to Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,

Board of Directors of  
Transgene Biotek Limited

Report on the Audit of Consolidated Financial Results

### **Opinion**


We have audited the accompanying statement of quarterly financial results of **TRANSGENE BIOTEK Limited** for the quarter ended 31 March 2022 and the year to date consolidated financial results for the period 01 April 2020 to 31 March 2022, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i. Includes the results of the Transgene Biotek HK Limited and PerOral Bio Private Limited..
- ii. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- iii. gives a true and fair view of the net profit/(Loss) and other financial information for the quarter ended 31 March 2022 as well as the year to date results for the period from 01 April 2021 to 31 March 2022.

### **Basis of Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the • Auditor's Responsibilities for the Audit of the Consolidated Financial Results • section of our report. We are independent of the Group, its associates and joint venture in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.





## **Management Responsibilities for the Financial Results**

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive Income and other financial information of the Group including its associates and joint venture in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. The respective Board of Directors of the companies Included in the Group and of its associates and joint venture are responsible for maintenance of adequate accounting records In accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and joint venture and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement. Whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either Intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**


Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

## **Other Matter**

The accompanying Statement includes the audited financial statements and other financial information, in respect of 1 subsidiary (the transaction are nil of the said subsidiary for the said FY 2021-22).

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial information certified by management.

The Statement includes the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2022 and the published






unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

We draw attention Note 01 to the statement, which describes the business impact and uncertainties arising from COVID 19 pandemic. This is based on current facts and circumstances and may not reflect future uncertainties and events arising from the full impact of the COVID 19 pandemic.

For Manisha Dubey & Associates  
Chartered Accountants  
Firm's Registration No. 0201145

Manisha Dubey  
Proprietor  
Membership No. 212664  
Hyderabad



**Unique Document Identification Number (UDIN) for this document is 22212664AJWEKE4103**

May 30, 2022

The General Manager  
Department of Corporate Services – CRD,  
Bombay Stock Exchange Limited (BSE),  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai 400 001.

**Scrip Code: 526139**

Subject: **Declaration pursuant to Regulations 33(3)(d) of SEBI (Listing obligations and Disclosure Requirement), Regulations, 2015.**

Dear Sir/Madam,


I, Dr K Koteswara Rao, Chairman & Managing Director of M/s Transgene Biotech Limited hereby declare that M/s. Manisha Dubey & Associates , Chartered Accountants of the Company (Membership No:212664) have issued unmodified opinion on Annual Audited Financial Results for the year ended 31<sup>st</sup> March 2022. (Consolidated & Standalone).

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We request you to kindly take the above-mentioned information on your records.

Thanking you,

**Yours faithfully,  
For TRANSGENE BIOTEK LIMITED**



**DR K KOTESWARA RAO  
CHAIRMAN & MANAGING DIRECTOR**